公开(公告)号：US11459385B2

公开(公告)日：2022-10-04

申请号：US16925227

申请日：2020-07-09

Applicant: Pfizer Inc. ,  The Regents of the University of California ,  The Board of Trustees of the Leland Stanford Junior University

Inventor： Isaac J. Rondon ,  Natasha Crellin ,  Paul Bessette ,  Eleonora Trotta ,  Jeffrey A. Bluestone ,  Lauren K. Ely ,  Kenan C. Garcia

IPC: C07K16/24 ,  A61K39/00

Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

公开(公告)号：US20190106488A1

公开(公告)日：2019-04-11

申请号：US16133939

申请日：2018-09-18

Applicant: Pfizer Inc. ,  The Regents of the University of California ,  The Board of Trustees of the Leland Stanford Junior University

Inventor： Isaac J. Rondon ,  Natasha Crellin ,  Paul Bessette ,  Eleonora Trotta ,  Jeffrey A. Bluestone ,  Lauren K. Ely ,  Kenan C. Garcia

IPC: C07K16/24

Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

公开(公告)号：US20230340106A1

公开(公告)日：2023-10-26

申请号：US17946941

申请日：2022-09-16

Applicant: Pfizer Inc. ,  The Regents of the University of California ,  The Board of Trustees of the Leland Stanford Junior University

Inventor： Isaac J. Rondon ,  Natasha Crellin ,  Paul Bessette ,  Eleonora Trotta ,  Jeffrey A. Bluestone ,  Lauren K. Ely ,  Kenan C. Garcia

IPC: C07K16/24

CPC classification number: C07K16/246 ,  C07K2317/76 ,  C07K2317/21 ,  C07K2317/51 ,  A61K2039/505

Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

公开(公告)号：US20230280341A1

公开(公告)日：2023-09-07

申请号：US17860014

申请日：2022-07-07

Applicant: The Regents of the University of California

Inventor： Jeffrey A. Bluestone ,  Weihong Liu ,  Amy Putnam

IPC: G01N33/569 ,  A61K39/00 ,  C12N5/0783 ,  G01N33/50 ,  A61K35/17

CPC classification number: G01N33/56972 ,  A61K39/0008 ,  C12N5/0636 ,  G01N33/505 ,  A61K35/17 ,  A61K2039/515 ,  G01N2333/70514 ,  G01N2333/70517 ,  G01N2333/70596 ,  A61K2035/122

Abstract: The invention provides methods of isolating CD 127lo/− immunosuppressive regulatory T cells which can be greatly enriched for FoxP3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.

公开(公告)号：US09801911B2

公开(公告)日：2017-10-31

申请号：US14382537

申请日：2013-03-01

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Qizhi Tang ,  Jeffrey A. Bluestone

IPC: C12N5/071 ,  C12N5/00 ,  C12N5/02 ,  A61K35/17 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  C12N5/0783 ,  A61K39/00 ,  C12N5/0781

CPC classification number: A61K35/17 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  A61K39/001 ,  A61K2300/00 ,  C12N5/0635 ,  C12N5/0637 ,  C12N2501/04 ,  C12N2501/2304 ,  C12N2501/515 ,  C12N2502/1107 ,  C12N2502/30

Abstract: The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants.

公开(公告)号：US20210147841A1

公开(公告)日：2021-05-20

申请号：US17089284

申请日：2020-11-04

Applicant: The Regents of the University of California

Inventor： Alexander Marson ,  Jeffrey A. Bluestone ,  Kathrin Schumann

IPC: C12N15/113 ,  C12N9/22 ,  C12N5/0783

Abstract: The disclosure features methods directed to modifying regulatory T (Treg) cell stability by inhibiting the expression of one or more transcription factors and/or inhibiting one or more genes or gene products regulated by the transcription factors. The disclosure also features compositions comprising the Treg cells having modified stability.

公开(公告)号：US20210061902A1

公开(公告)日：2021-03-04

申请号：US16925227

申请日：2020-07-09

Applicant: Pfizer Inc. ,  The Regents of the University of California ,  The Board of Trustees of the Leland Stanford Junior University

Inventor： Isaac J. RONDON ,  Natasha Crellin ,  Paul Bessette ,  Eleonora Trotta ,  Jeffrey A. Bluestone ,  Lauren K. Ely ,  Kenan C. Garcia

IPC: C07K16/24

Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

公开(公告)号：US10227290B2

公开(公告)日：2019-03-12

申请号：US14376747

申请日：2013-02-07

Applicant: The Regents of the University of California ,  President and Fellows of Harvard College

Inventor： Michael A. Fischbach ,  Jeffrey A. Bluestone ,  Cristina Penaranda ,  Laura Brown ,  Jon Clardy

IPC: A61K35/12 ,  A61K35/26 ,  C07H15/04 ,  C07H15/06 ,  C12P13/02 ,  C12P19/44 ,  C07C235/08 ,  C07F9/141

Abstract: Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.

公开(公告)号：US20170114130A1

公开(公告)日：2017-04-27

申请号：US15331038

申请日：2016-10-21

Applicant: Pfizer Inc. ,  The Regents of the University of California ,  The Board of Trustees of the Leland Stanford Junior University

Inventor： Isaac J. Rondon ,  Natasha Crellin ,  Paul Bessette ,  Eleonora Trotta ,  Jeffrey A. Bluestone ,  Lauren K. Ely ,  Kenan C. Garcia

IPC: C07K16/24

CPC classification number: C07K16/246 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

公开(公告)号：US12103958B2

公开(公告)日：2024-10-01

申请号：US17035327

申请日：2020-09-28

Applicant: PFIZER INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Natasha Kay Crellin ,  Lauren Kate Ely ,  Jason Robles Reyes ,  Chia Chi Ho ,  Jeffrey A. Bluestone ,  Eleonora Trotta ,  Qizhi Tang

IPC: C07K14/705 ,  A61K39/00 ,  C12N15/63 ,  G01N33/50 ,  G01N33/68

CPC classification number: C07K14/70528 ,  A61K39/001129 ,  C12N15/63 ,  G01N33/505 ,  G01N33/68 ,  C07K2319/30 ,  G01N2333/70507

Abstract: The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.